Study of Vaccine Production Abroad and Scientific and Research Challenges of COVID-19 Vaccine Production in Iran

Abstract

Coronaviruses are enveloped viruses with single-stranded RNA that cause acute lung disease in a range of animal species, including humans. After the outbreak of the Coronavirus in 2019, the world economy entered a recession. Social and business relations became limited and the livelihoods of many people around the world were hampered. Meanwhile, in the absence of effective treatment against this disease, vaccine production is one of the major solutions to get out of the current critical situation. With the approval of COVID-19 vaccines for use in different parts of the world, the scale and complexity of their production, allocation, and distribution worldwide is unprecedented. However, vaccine production by both large foreign and domestic companies is fraught with challenges that have made public vaccination obscure in the short term. The risks of corruption, such as the entry of substandard and counterfeit vaccines into markets and the production budget leakage, may threaten the vital goals of vaccine production and public health. It is recommended that the general population not be tested by mistake until a safe domestic vaccine is obtained. As a result, any hasty action to provide the vaccine may induce irreparable consequences.